PHP
EPIX

Parkman Healthcare Partners’s ESSA Pharma EPIX Stock Holding History

Parkman Healthcare Partners’s Portfolio EPIX Stock Details EPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-345,902
Closed -$2.1M – 96
2024
Q3 		$2.1M Buy
345,902
+93,830
+37% +$515K 0.27% 74
2024
Q2 		$1.33M Buy
252,072
+377
+0.1% +$2.4K 0.18% 78
2024
Q1 		$2.14M Buy
+251,695
New +$2.2M 0.26% 84

Other funds holding EPIX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Parkman Healthcare Partners's EPIX Position: Q4 2024 in Review

Parkman Healthcare Partners sold out of ESSA Pharma (EPIX) in Q4 2024, closing a stake of 345,902 shares — an estimated $2.1M sold.

Parkman Healthcare Partners first reported a position in EPIX in Q1 2024 and held it in 3 quarters. The position peaked at $2.14M in Q1 2024. 46 funds tracked by Wall St. Rank hold EPIX as of Q4 2024.

  • Parkman Healthcare Partners reported no remaining ESSA Pharma position as of Q4 2024 after selling out during the quarter.
  • Parkman Healthcare Partners sold 345,902 ESSA Pharma shares in Q4 2024, an estimated $2.1M.
  • Parkman Healthcare Partners first reported a position in ESSA Pharma in Q1 2024 and held it in 3 quarters.
  • Parkman Healthcare Partners's ESSA Pharma position peaked at $2.14M in Q1 2024.
  • 46 funds tracked by Wall St. Rank held ESSA Pharma as of Q4 2024.

Based on Parkman Healthcare Partners's 13F filing for Q4 2024, filed 14 Feb 2025.